What is HC Wainwright’s Estimate for PRAX FY2026 Earnings?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) – Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Praxis Precision Medicines in a research report issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($13.45) per share for the year, up from their prior estimate of ($14.09). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Praxis Precision Medicines’ current full-year earnings is ($14.03) per share.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its earnings results on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating the consensus estimate of ($3.54) by $0.31.

Several other equities research analysts have also commented on PRAX. BTIG Research reiterated a “buy” rating and set a $826.00 price target on shares of Praxis Precision Medicines in a research note on Monday. Robert W. Baird set a $514.00 price objective on Praxis Precision Medicines in a research report on Friday, August 7th. Wedbush boosted their price target on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the stock an “underperform” rating in a research note on Tuesday. Royal Bank Of Canada upped their price objective on Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Raymond James Financial restated a “strong-buy” rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research report on Monday, August 17th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $631.68.

Praxis Precision Medicines Stock Up 2.6%

Shares of Praxis Precision Medicines stock opened at $346.21 on Thursday. The firm’s 50 day moving average is $291.10 and its two-hundred day moving average is $314.16. The firm has a market capitalization of $9.67 billion, a P/E ratio of -27.05 and a beta of 2.85. Praxis Precision Medicines has a 52 week low of $160.11 and a 52 week high of $392.70.

Institutional Investors Weigh In On Praxis Precision Medicines

Several hedge funds have recently modified their holdings of PRAX. Janus Henderson Group PLC grew its position in shares of Praxis Precision Medicines by 6.8% in the first quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock valued at $1,113,514,000 after purchasing an additional 218,777 shares during the period. Perceptive Advisors LLC increased its holdings in shares of Praxis Precision Medicines by 2.0% during the 1st quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock worth $655,974,000 after buying an additional 40,000 shares during the last quarter. Bank of America Corp DE raised its position in shares of Praxis Precision Medicines by 2.3% in the 1st quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock worth $172,244,000 after buying an additional 11,841 shares during the period. Vivo Capital LLC lifted its stake in shares of Praxis Precision Medicines by 3.0% in the 1st quarter. Vivo Capital LLC now owns 338,895 shares of the company’s stock valued at $109,189,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Aberdeen Group plc lifted its position in Praxis Precision Medicines by 28.2% during the third quarter. Aberdeen Group plc now owns 213,400 shares of the company’s stock valued at $62,148,000 after buying an additional 47,001 shares in the last quarter. 67.84% of the stock is owned by institutional investors and hedge funds.

Key Praxis Precision Medicines News

Here’s some of the latest news about PRAX:

• Positive Sentiment: BTIG and RBC Capital issued “Buy” ratings. RBC also raised its price target to $478 from $462 and maintained an “Outperform” rating, signaling confidence in potential appreciation. BTIG Buy rating RBC Capital Buy rating
• Positive Sentiment: The company recently reported quarterly earnings that exceeded analysts’ expectations, a result associated with a prior rally in PRAX shares.
• Neutral Sentiment: Praxis presented at the Guggenheim Healthcare Innovation Conference; the provided coverage is a transcript and does not identify a specific new catalyst.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.